Evaluation of miR-625 and miR-302a Expression in Renal Cell Carcinoma

• Published in: Journal of pioneering medical sciences Vol. 8; no. 2; pp. 60 - 66
• Main Authors: Ali Bazrafshan, Zahra Davari Varanlou, Alireza Shahryari, Nader Mansour Samaei, Mohammad Shafiee, Naeme Javid, Behnaz Bazrafshan, Sepideh Siadati, Mohsen Saeidi
• Format: Journal Article
• Language: English
• Published: JOURNAL OF PIONEERING MEDICAL SCIENCES 01.09.2018
• Subjects: Human; Gene Expression; Carcinoma; Real-Time Polymerase Chain Reaction; MicroRNAs; miR-625
• ISSN: 2309-7981; 2309-7981

BACKGROUND: Renal cell carcinoma (RCC) is the most common and malignant tumor of kidney tissue, with unknown molecular mechanism and pathogenesis. Recent studies have demonstrated that micro ribonucleic acids (miRNAs) may have potential role in initiation and progression of RCC. In this study we evaluated expression patterns of two RNA molecules, miR-625 and miR-302a in tumor and non-tumor portions of RCC samples. METHODS: The relative expression levels of miR-625 and miR-302a were delineated by real-time PCR in 20 formalin-fixed paraffin-embedded (FFPE) RCC samples and compared with 20 non-tumor matched samples obtained from margins of the same samples. RESULTS: We found approximately 15-fold increase in miR-625 expression in tumor samples compared to non-tumor samples of each patient, but it was not a significant difference (P Value: 0.097). On the other hand, miR-302a expression was similar between tumor and non-tumor sections of the sample (P Value ＞ 0.05). Additionally, we did not find an association between age, gender, grade and stage of tumors, and expression level of either of the two miRNAs. CONCLUSION: Our data demonstrated that there is no significant difference of miR-625 and miR-302a expression in tumor samples of RCC when compared to non-tumor samples. We further found no relationship between clinico-pathological characteristics and expression levels of miR-625 or miR-302a.